BACE1 inhibition by microdose lithium formulation NP03 rescues memory loss and early stage amyloid neuropathology

Lithium is first-line therapy for bipolar affective disorder and has recently been shown to have protective effects in populations at risk for Alzheimer’s disease (AD). However, the mechanism underlying this protection is poorly understood and consequently limits its possible therapeutic application...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilson, E N, Do Carmo, S, Iulita, M F, Hall, H, Ducatenzeiler, A, Marks, A R, Allard, S, Jia, D T, Windheim, J, Cuello, A C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5611736/
https://www.ncbi.nlm.nih.gov/pubmed/28763060
http://dx.doi.org/10.1038/tp.2017.169

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5611736/
https://www.ncbi.nlm.nih.gov/pubmed/28763060
http://dx.doi.org/10.1038/tp.2017.169

Ejemplares similares